Tumor metastasis is the leading cause of death among breast cancer patients. PELP1 (proline, glutamic acid and leucine rich protein 1) is a nuclear receptor coregulator that is upregulated during breast cancer progression to metastasis and is an independent prognostic predictor of shorter survival of breast cancer patients. Here, we show that PELP1 modulates expression of metastasis-influencing microRNAs (miRs) to promote cancer metastasis. Whole genome miR array analysis using PELP1-overexpressing and PELP1-underexpressing model cells revealed that miR-200 and miR-141 levels inversely correlated with PELP1 expression. Consistent with this, PELP1 knockdown resulted in lower expression of miR-200a target genes ZEB1 and ZEB2. PELP1 knockdown significantly reduced tumor growth and metastasis compared with parental cells in an orthotopic xenograft tumor model. Furthermore, re-introduction of miR-200a and miR-141 mimetics into PELP1-overexpressing cells reversed PELP1 target gene expression, decreased PELP1-driven migration/invasion in vitro and significantly reduced in vivo metastatic potential in a preclinical model of experimental metastasis. Our results demonstrated that PELP1 binds to miR-200a and miR-141 promoters and regulates their expression by recruiting chromatin modifier histone deacetylase 2 (HDAC2) as revealed by chromatin immunoprecipitation, small interfering RNA and HDAC inhibitor assays. Taken together, our results suggest that PELP1 regulates tumor metastasis by controlling the expression and functions of the tumor metastasis suppressors miR-200a and miR-141.
INTRODUCTION
Breast cancer is the most frequently diagnosed cancer in women. Metastases spawned by malignant tumors are responsible for the majority of breast cancer-related morbidity and mortality. 1 Tumor metastasis comprises a series of discrete biological processes that move tumor cells from the primary neoplasm to a distant location 2 and involves a multistep cascade of coordinated cell adhesion and contractility as well as a proteolytic remodeling of the extracellular matrix. 3 Even though the currently used breast cancer-targeted therapies directed against nuclear receptors such as the estrogen receptor (ER) and growth factor receptors such as human epidermal growth factor receptor 2 (HER2) are effective in curbing the localized disease, these therapies are less effective in treating metastases. Furthermore, a substantial number of patients treated with targeted therapies acquire resistance over a period of time and the tumors recur as metastases. Even though significant information is available on the process of metastasis, a critical need still exists to identify novel targets that can be used to curb the progression of breast cancer metastasis.
The microRNA (miR)-mediated regulation of tumorigenesis is emerging as a new paradigm in the field of cancer biology. Misexpression of miR occurs in many cancers, including breast cancer. The miRs play critical roles in diverse biological processes, aberrantly expressed in breast tumors and function as regulators of tumor behavior and progression. 4, 5 They are also involved in multiple steps in the metastatic cascade by influencing cancer cell adherence, migration, invasion, motility and angiogenesis. 6 The class of miRs associated with metastatic process was recently termed metastamir. 7 The metastasis-promoting metastamir (such as miR-21, miR-373 and miR-155) enhance breast cancer metastasis, 8 whereas metastasis-suppressing metastamirs (such as miR-200, miR-145 and miR-661) inhibit metastasis with minimum effects on orthotropic tumor growth. 8 The molecular mechanism of miR deregulation and how such deregulation contributes to breast cancer metastasis remains elusive and is an area of significant importance.
Nuclear receptors (NR) play an important role in breast cancer progression and their signaling is complex, involving coregulators. 9 Emerging evidence suggests that metastatic tumors express increased levels of coregulators, that NR coregulators have the potential to activate an appropriate set of genes to produce a desired goal such as cell growth via their interactions with multiple NRs [10] [11] [12] and that their deregulation provides the cancer cells an advantage in growth and metastasis. Accordingly, several NR coregulators including steroid receptor coactivator-3 (SRC-3)/ AIB1, metastasis tumor antigen 1 (MTA1), nuclear receptor corepressor (NCoR) complex and its paralog, silencing mediator of retinoid and thyroid hormone receptor (SMRT), and histone deacetylase (HDAC) are shown to play important roles during key steps in the invasion-metastasis cascade. 13, 14 How the coregulator signaling influences metastasis and whether the coregulator signaling involves miRs remain poorly understood. PELP1 (proline, glutamic acid and leucine rich protein 1) is an NR coregulator that interacts with multiple hormonal receptors and exhibits aberrant expression in many hormone-related cancers. 15, 16 PELP1 functions as proto-oncogene 17 and its expression is upregulated in metastatic tumors. It is a prognostic indicator of shorter breast cancer-specific survival and disease-free interval. Recent studies from our lab have uncovered a pivotal role for PELP1 signaling in breast cancer cell migration and metastasis 18 and demonstrated that PELP1 has the potential to modulate expression of genes involved in metastasis. PELP1 overexpression is equally observed in both ER-positive and ER-negative metastatic tumors, suggesting that PELP1 may have functions independent of the ER in metastatic cells. 17, 18 Collectively, these published studies strongly suggest a role of PELP1 in metastasis; however, the mechanism by which PELP1 modulates metastasis genes and whether PELP1 signaling involves regulation of miR remain unknown.
In this study, we investigated the molecular mechanism and significance of PELP1-miR signaling axis in the regulation of breast cancer metastasis. Our results suggest that PELP1 plays a role in breast cancer metastasis by modulating expression of tumorsuppressor miR-200a and miR-141. These novel findings suggest that PELP1-miR axis may be a crucial stimulus for promoting breast cancer metastasis.
RESULTS

PELP1 modulates expression of miR-200a and miR-141
PELP1 is a proto-oncogene that functions as coregulator of several nuclear receptors with deregulated expression in metastastic tumors. We tested the hypothesis that PELP1 modulation of miRs contributes to its metastasis potential. For these assays, we used ZR75 models that stably express the PELP1, PELP1-shRNA or control-shRNA vector. Compared with the ZR75 vector cells, the ZR75PELP1-shRNA cells express an 80% reduction in endogenous PELP1 expression, whereas PELP1-overexpressing cells had an eightfold increase in PELP1 transcript over endogenous PELP1 (Supplementary Figure S1A and B) . We recently demonstrated that ZR-PELP1 model cells exhibit oncogenic properties and metastatic potential 17 whereas PELP1-shRNA cells exhibit decreased metastasis. 18 To investigate the general effect of PELP1 deregulation on miR expression, whole-genome miR array analysis was performed by using the human miRCURY LNA microarrays (Exiqon, Woburn, MA, USA). The PELP1 status significantly affected the miR expression profiles, as several miRs were found significantly downregulated in PELP1-overexpressing cells and PELP1 knockdown significantly increased the expression of these miRs ( Figure 1a) . We used real-time qPCR to validate the expression of the top 10 miRs with the highest fold change from array results (Supplementary Figure S1C) . Results of confirmation for two representative miRs are shown in Figure 1b . The real-time quantitative PCR results confirmed that PELP1 deregulation suppressed selective miRs, whereas PELP1 knockdown enhanced their expression. Among the PELP1-regulated miRs, we focused on miR200a and miR141 as these two miRs are implicated in the epithelial-to-mesenchymal transition (EMT) and the metastasis processes of the cells. 19 To confirm the results obtained from PELP1 stable model cells, we further validated the results by using transient knockdown with PELP1 siRNA that targets a different site on PELP1 than the PELP1-shRNA targeted site. In these assays, transient knockdown of PELP1 expression also substantially enhanced the expression of miR-200a and miR-141 in two ER-positive model cell lines MCF7 and ZR75 (Figure 1c) . Interestingly, PELP1 also has the potential to regulate expression of miR-200a and miR-141 in ER-negative breast cancer model cells MDA-MB-231 and MDA-MB-468 (Supplementary Figure S1D and E), suggesting PELP1 regulation of miR-200a and miR-141 is independent of ER-a. Collectively, these results suggest that the proto-oncogene PELP1 has the potential to regulate the expression of miR-200a and miR-141. Figure S2A family members in the regulation of EMT genes. 19 As our earlier studies showed that PELP1 has the potential to regulate genes involved in EMT, 18 we tested the hypothesis that PELP1 regulation of EMT genes may involve miR-200 family members. Western analysis revealed that miR-200a and miR-141 antagomirs reversed PELP1-shRNA-mediated alterations in EMT genes in ER-positive cells (Figure 2c and Supplementary Figure S2C) . Accordingly, in reporter gene-based assays, PELP1-shRNA cells exhibited less ZEB1 and ZEB2 3 0 -untranslated region (UTR) luciferase reporter activity than the activity in control-shRNA cells, and the PELP1 knockdown-mediated repression of reporter activity was relieved by the miR-200a and miR-141 antagomirs (Figure 2d) . Similarly, miR-200a and miR-141 antagomirs also reversed PELP1-shRNA-mediated changes in EMT genes in ER-negative model cells (Figures 2e and  f) . Collectively, these results suggest that PELP1-mediated cell migratory/invasion functions involve the miR-200a and miR-141 family members. (Figure 3a) . Published studies suggested that PELP1 modulates the expression of genes either by modulating epigenetic changes via its interaction with chromatin modifying enzymes or by promoting nongenomic actions via Src, phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
As PELP1 regulated expression of miR family members in both ER þ and ER À cells, we initially examined whether PELP1-mediated nongenomic actions may play a role in PELP1 regulation of miRs. To test this we have performed miR-200-promoter-Luc assays in the presence or absence of specific inhibitor of Src, phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. All three inhibitors failed to block PELP1-mediated suppression of miRs (Supplementary Figure S3A and B) . We then tested whether PELP1-mediated genomic actions may play a role in modulation of miR expression and tested if PELP1 is recruited to the promoter region of miR200. Previous studies have shown the promoter region containing À 156 to þ 83 relative to premiRNA200b-200a-429 as the proximal promoter that contains regulatory elements for transcription of miR200b-200a-429. 22, 23 The chromatin immunoprecipitation (ChIP) results showed that PELP1 is recruited to the proximal promoter region À 156 to þ 83 of 200b-200a-429. We have also used distal promoter region ( À 1088 to À 920) as a control and no recruitment of PELP1 was observed in that region ( Figure 3b ). We next tested PELP1 recruitment to miR200c-141 promoter using primers that encompass À 236 to À 107 promoter region of miR 200c-141. We focused our ChIP studies to this region based on earlier published studies that suggested that À 236 to À 107 have regulatory elements that control miR200c-141 promoter, and this region is subjected to epigenetic regulation. 22, 24 ChIP results confirmed PELP1 ability to recruit to miR200c-141 promoter ( Figure 3c ). These results suggest that PELP1 has the potential to recruit to miR-200 promoters and that PELP1-mediated genomic actions may play a role in the regulation of these miRs. PELP1 does not possess any known enzymatic activity. However, published studies demonstrated that PELP1 interacts with several chromatin-modifying enzymes including histone acetyl transferases and KDM1 (lysine-specific demethylase 1) and has the potential to alter epigenetic marks at the target gene promoters. 25, 26 We therefore examined the status of the histone epigenetic modifications at the proximal promoters of miR-200a and miR-141. ChIP analysis revealed that PELP1 knockdown enhanced the active histone mark H3K9Ac at the promoters of both miR-200a and miR-141 (Figure 3d ). ChIP analysis with H3K9Me2 also revealed that PELP1 knockdown reduces Figure S3C) . These results suggest that PELP1-mediated alteration in epigenetic modifications may play a role in the modulation of the expression and function of miR-200 family genes by PELP1.
HDAC2 and PELP1 interaction play a critical role in regulation of miR-200 family members Previous published findings established that PELP1 interacts with the histone deacetylase HDAC2. 25 Upregulation of H3K9Ac at the miR promoter region in PELP1-knockdown cells suggests a possibility that the PELP1 interaction with the HDAC2 enzyme may contribute to the alteration in acetylation levels at the miR-200 promoters. The ChIP assay with HDAC2 demonstrated the recruitment of HDAC2 at the regulatory regions of both miR promoters (Figure 4a ). The role of PELP1 in HDAC2 recruitment at the miR-200 promoters was further examined by performing a ChIP assay with HDAC2 in ZR-PELP1-shRNA cells (Figure 4a ). Diminished recruitment of HDAC2 to the miR promoter regions was found in the absence of PELP1. Accordingly, treatment with the HDAC inhibitor Trichostatin A reversed PELP1-driven repressive effects on both miR200c-141 and miR200b-200a-429 promoter activities (Figure 4b ). To further confirm the role and specificity of HDAC2 in PELP1-mediated regulation of miR-200a and miR-141, we have used HDAC2-siRNA. Nontargeting, HDAC1 and HDAC3 siRNAs were used as additional controls and siRNA specificity was validated by western blotting (Supplementary Figure S3D) . The results showed that only HDAC2 siRNA, but not HDAC1 or HDAC3 siRNAs, was able to reverse PELP1-mediated repression of miR-200a and miR-141 in miR promoter reporter assays (Figures 4c and d) . studies demonstrated the therapeutic efficacy of the mimetics of metastasis suppressors miR-200a and miR-141 on PELP1-driven in vivo breast cancer cell colonization and outgrowth.
DISCUSSION
Metastatic breast cancer is the leading cause of death in patients diagnosed with advanced-stage breast cancer. A critical need still exists to identify novel therapeutic targets to treat this metastasis. Metastasis is complex process, requiring coordinated activation of multiple genes and pathways. 27 During the past decade, research has provided evidence to suggest that alterations in the levels of coregulator concentrations or the genetic dysfunction of NR coregulators can contribute to a pathologic outcome by modulating genes and pathways that drive cancer cell proliferation and metastasis. 28 Whether the NR coregulator signaling is also involved in the activation of miRs that contribute to metastasis remains unknown. In this study, we found that (1) the NR coregulator PELP1 modulates the expression of several metastasis suppressing miRs, (2) PELP1 recruits to promoters of the miR200 family members and promotes epigenetic changes and (3) miR regulation plays a critical role in PELP1-mediated in vivo metastasis. Mechanistic studies suggested that under conditions of PELP1 deregulation, miR-200 is silenced by the PELP1-HDAC2 complex that deacetylates histones. These findings were further validated in PELP1 knockdown experiments that showed the disruption of the interaction of the PELP1-HDAC2 complex, leading to re-expression of miR-200a/141 by increasing acetylated histone marks at the miR-200 promoter (Figure 5d ). Collectively, these novel findings demonstrate a new role for PELP1 in epigenetically controlling the functions of the tumor metastasis suppressors miR-200a and miR-141 and thus contributing to metastasis.
The miR-200 family comprises five members and clusters in two genomic loci (200b-200a-429 and 200c-141) . The expression of miR-200 family is lost in the regions of metaplastic breast cancer specimens and metastases. 19 The miR-200 family regulates EMT by targeting 3 0 UTR of ZEB1 and SIP1. 19 Some evidence suggests that ZEB1 suppresses the transcription of the miR-200 family members, 22, 29 indicating reciprocal repression between ZEB1 and members of the miR-200 family in EMT and invasion of cancer cells. Although the role of the miR-200 family members in EMT is well established, the mechanism by which oncogenes regulate miR-200 family members is elusive. Our data suggested that the protooncogene PELP1 has the potential to modulate expression of miR-200 family members. PELP1 interacts with several chromatinmodifying enzymes, including histone-modifying acetylases, deacetylases, methyltransferases and demethylases. 29, 30 Our mechanistic studies revealed that PELP1 is recruited to the promoters of miR-200 family members and modulates their expression by promoting repressing epigenetic marks. Furthermore, these studies revealed that the interactions of PELP1 with HDAC2 play a critical role in this process and HDAC inhibitor can reverse PELP1-mediated suppression of miR-200 family members. Collectively, these studies indicate PELP1 deregulation as having the potential to suppress expression of tumor-suppressor miRs by facilitating repressive epigenetic changes.
Loss of the epithelial adhesion molecule E-cadherin is implicated as having a critical role in metastasis by disrupting intercellular contacts, an early step in metastatic dissemination. 30 Functional or transcriptional loss is commonly associated with an invasive and poorly differentiated phenotype. 31 Deregulation of NR coregulator signaling can lead to aberrant expression of Snail, resulting in the loss of expression of E-cadherin and invasive growth. For example, MTA1, a commonly deregulated coregulator in breast cancer, promotes transcriptional repression of ER, leading to metastatic progression. 32 The NR coregulator AIB1 amplified in breast cancer promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase-2 and -9 expression. 33 SRC-1, another NR coregulator, has also been shown to promote breast cancer invasiveness and metastasis by coactivating PEA3-mediated Twist expression. 34 Recent studies have also found deregulation of the NR coregulator PELP1 in invasive and metastatic breast tumors, 17 and its elevated expression is positively associated with markers of poor outcome. 35 The results from our studies for the first time linked NR coregulator PELP1 with epigenetic silencing of breast cancer metastasis suppressing miRs.
PELP1 interacts with several proteins involved in migratory functions, including phosphoinositide 3-kinase, 21 four-and-a-half LIM protein 2, 36 ILK1, 37 and MTA1, which is a protein implicated in metastasis. Our recent studies demonstrated that PELP1 contributes to the metastatic potential of both ER þ and ER À breast cancer cells. Such studies indicate that PELP1 regulation of metastasis may involve a mechanism that is independent of its ER coactivaton functions. Our study results provided strong evidence that PELP1 directly recruits and suppress expression of several miRs that regulate metastasis including miR-200a and miR-141. Accordingly, miR-200a and miR-141 mimetics blocked PELP1-mediated migration and invasion in vitro and metastasis in vivo. PELP1 regulated expression of miR similarly in ER þ and ER À cells, further confirming that this regulation is independent of the ER. As PELP1 expression is commonly deregulated in metastatic tumors, PELP1 regulation of miRs may have implications in tumor progression to metastasis. In spite of significant progress in the understanding of the etiological role of PELP1 in breast cancer progression and its mechanism of action, no drugs are currently available to target PELP1. On the basis of our results, we speculate that drugs targeting PELP1-miR200 axis can be used to target PELP1-driven tumor progression to metastasis.
In summary, our study demonstrates for the first time that PELP1 modulates the expression of miRs and PELP1-regulated miRs play a critical role in breast cancer metastasis. Furthermore, we provided evidence that PELP1-mediated epigenetic changes have an important role in the modulation of miRs involved in metastasis. PELP1-modulated miR signatures may serve as useful biomarkers and novel targets for the therapeutic intervention of PELP1-driven tumors; however, further studies are needed to understand the prognostic significance of the PELP1-miR axis.
MATERIALS AND METHODS
Cell cultures and reagents ZR-75, MCF7, MDA-MB-231 and MDA-MB-468 cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI-1640 supplemented with 10% fetal bovine serum. All model cells were passaged in the user's laboratory for o6 months after receipt or resuscitation. PELP1, Snail, E-cadherin, Vimentin and ZEB1 antibodies were purchased from Bethyl Laboratories (Montgomery, TX, USA) and Cell Signaling (Beverly, MA, USA). Matrigel and n-cadherin antibodies were purchased from BD transduction (San Jose, CA, USA). Occludin and HDAC 1,2,3 antibodies were purchased from Life Technologies (Grand Island, NY, USA) and Active Motif (Carlsbad, CA, USA). TUNEL kit for apoptosis detection was purchased from Roche (Mannheim, Germany) and Ki-67 anti human Clone MiB-1 antibody was purchased from Dako (Carpinteria, CA, USA). miRCURY LNA miR Inhibitor and miRIDIAN miR Mimics for hsa-miR200a and hsa-miR-141 were purchased from Exiqon and Dharmacon (Lafayette, CO, USA) respectively. Control, HDAC1, HDAC2 and HDAC3 siRNAs were purchased from Qiagen (Germantown, MD, USA). The plasmids encoding the promoter reporter of 200c-141 containing À 796 to þ 290 ( Chang et al.
38
) and 200b-200a-429 clusters containing region À 1574 to þ 120 (Brackan et al. 22 ) as well as the ZEB1 and ZEB2 3 0 UTR luciferase reporter 19 have been described previously.
Generation of model cells
Non-metastastic, ER-positive (ZR75 and MCF7) and metastatic, ER-negative (MDA-MB-231 and MDA-MB-468) models that either stably overexpress PELP1 promotes metastasis through miR-200 pathway SS Roy et al PELP1 or PELP1-shRNA were developed as described previously. 18 Transient knockdown of PELP1 was achieved using OnTargetPlusSMARTpool siRNA from Dharmacon. Breast cancer cells stably expressing PELP1 were transfected with human miRIDIAN shMIMIC lentiviral miR (Open Biosystems, Thermo-Fisher Scientifics, Huntsville, AL, USA) for longterm expression of miR-200a and miR-141. Stable clones were selected with puromycin selection (1 mg/ml) and pooled clones were used for all studies. Human shMIMIC lentiviral miR Non-Silencing control was used to generate control cells.
Microarray studies
Total RNA that was isolated from the ZR control and ZR cells stably overexpressing PELP1cDNA or PELP1-shRNA were used for microarray analysis. The miR microarray profiling was done by Exiqon using the Human miRCURY LNA Array. Target miR whose expression was differentially regulated (at least twofold difference) by PELP1 expression was selected and validated by using real-time PCR analysis. Briefly, total RNA was extracted by using the miRNEasy Mini kit (Qiagen, Valencia, CA, USA), 2 mg of total RNA was reverse transcribed by using the miScript RT kit (Qiagen) and real-time PCR was performed with a forward primer specific to miR by using the miScript SYBR Green PCR kit (Qiagen). Triplicate reactions were run for each complementary DNA sample. The relative expression of each miR was quantified by measuring Ct values and normalized by using RNU19. All real-time PCR primers that were used for validation of PELP1-regulated genes were purchased from RealTimePrimers (Elkins Park, PA, USA).
Cell migration, invasion and luciferase reporter gene assays
The cell migration and invasion assays were carried out by using the calorimetric cell migration assay kit (Millipore, Billerica, MA, USA) and the BD Biocat growth factor-reduced Matrigel invasion chamber kit (BD Biosciences, San Jose, CA, USA), respectively, as described in the manufacturer's protocol. 21 The pRL-ZEB1 and ZEB2 3'UTR luciferase reporter and the promoter reporter for two clusters in the two different genomic loci miR200b-200a-429 and miR200c-141 were used for the reporter gene assays by using FuGENE6 (Roche, Indianapolis, IN, USA) transient transfection method. 18 Cells were lysed in passive-lysis buffer 36-48 h after transfection, and the luciferase assays were performed using a luciferase assay kit (Promega, Madison, WI, USA). Each transfection was carried out in six-well plates in triplicate and normalized with either b-gal activity or the total protein concentration.
ChIP assays
ChIP analysis was performed as described previously. 39 Briefly, cells were crosslinked using 1% formaldehyde, and the chromatin was subjected to immunoprecipitation using the indicated antibodies. Isotype-specific IgG was used as a control. DNA was resuspended in 50 ml of TE buffer and used for real-time PCR amplification using the gene-specific primers ) were injected into mammary fat pad of 6-week-old female nude mice (n ¼ 5 per group, 10 tumors) as described previously. 26 Athymic nude mice (nu/nu) were injected with control MDAMB231-shRNA and MDAMB-231-PELP1 shRNA cells by mixing them with equal volume of Matrigel Matrix (BD Biosciences) to both left and right side of mammary fat pad. For experimental metastasis model, cells (1 Â 10 5 ) in serum-free medium were injected into left cardiac ventricle of 5-week-old female athymic nude mice (n ¼ 10 per group) as described previously. 18 ZR-PELP1 cells and ZR-PELP1 model cells that stably express miR-200a and miR-141 were transfected with green fluorescent protein (GFP)-Luc plasmid to monitor metastasis with whole animal imaging. [40] [41] [42] The mice were monitored daily for adverse effects and the body weight was recorded every week. The Xenogen Small-Animal Imaging System was used for subcellular imaging in live mice once a week. On day 40, mice were killed and the number of micrometastatic tumor nodules in the lungs was counted with an inverted microscope. Lung and tumor tissues were fixed in 10% neutral buffered formalin (Fisher Scientific, Pittsburgh, PA, USA) for 48 h at room temperature and embedded in paraffin.
Immunofluorescence and immunohistochemical analysis Immunofluorescence was performed as described previously. 37 The F-actin status was analyzed by phalloidin staining. Immunohistochemical analysis was performed as described previously. 26 Sections were stained with hematoxylin and eosin using UTHSCSA Pathology core protocol. Antibody dilutions are vimentin (1:50) and Ki-67 (1:150). Proliferative index was calculated as the percentage of Ki-67-positive cells in 10 randomly selected microscopic fields at Â 20 per slide. TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) analysis was done using the in situ Cell Death Detection Kit (Roche) as per the manufacturer's protocol and 10 randomly selected microscopic fields in each group were used to calculate the relative ratio of TUNEL-positive cells.
Statistical analysis
Statistical differences among groups were analyzed using either Student's t-test or analysis of variance as appropriate using SPSS software (IBM, Chicago, IL, USA). The P-values of o0.05 were considered significant. Error bars on the graphs show s.e.m.
